Coya Therapeutics, Inc. (COYA)
收市後：
- Benzinga
Coya Therapeutics' Alzheimer's Candidate Shows Lower Biomarker Levels Associated With Neuroinflammation
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for low-dose interleukin 2 (ld IL-2) in patients with Alzheimer's disease (AD). The study enrolled eight patients with confirmed brain amyloid pathology and baseline Mini-Mental State Examination test (MMSE) scores, a measure of cognitive function, between 12 and 25. The patients were treated with five-day courses of subcutaneous ld IL-2 for four monthly cycles and were followed for two month
- Benzinga
Why Coya Therapeutics Shares Are Shooting Higher Today
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with Alzheimer's disease. Treatment with COYA 301 resulted in a statistically significant improvement in cognitive function, as measured by the Mini-Mental State Examination test (MMSE), compared to the mean MMSE score at baseline (p=0.015). Consistent with the positive trend in MMSE score, mean scores in ADAS-Cog and CDR-SB scales did not significantly change at the
